Susan J. Aluise

Susan J. Aluise

Susan J. Aluise is president and executive editor of National News Syndicate, a Washington, D.C.-based news organization focused on global business, national security, information technology, transportation and financial services. Prior to forming the company in January 1996, she spent a decade at Potomac, Md.-based Phillips Business Information — the last six years as editorial director. She has launched 31 subscription-based news publications and websites in the Aviation, Financial Services, Defense, Information Technology and Telecom industries, including Aviation Today, World Airport Week, Credit Risk Management Report and Electronic Commerce Insider. In a journalism career spanning more than 30 years, Susan has covered six U.S. presidents and 15 Congresses for a variety of U.S. and global news organizations. She also has covered several international political and economic summits and was honored by a national journalism foundation for excellence in news and analysis following the 9/11 terror attacks.

Recent Articles

Our Picks for the Best CEOs of 2014

It’s easy to hate CEOs with their exorbitant salaries, perks and stock options – particularly when missteps by high-profile corner office occupants like Sears Holdings’ (SHLD) Eddie Lampert and United Technologies (UTX) chief Louis Chenevert led to their unceremonious exits in 2014. But some CEOs did it right in 2014.

3 Precious Metals ETFs for 2015

With precious metals having fallen so far, so fast, the right precious metals ETFs can help position investors for a rebound.

3 Undervalued Dividend Stocks to Buy Now

If you’re an income investor, dividend stocks are a valuable part of your portfolio -- but don't chase valuations. Buy these 3 cheap stocks!

4 Tough Challenges Facing Ford Stock

Ford is facing significant near-term challenges in 2015. But as the stock gets cheaper, it could prove a bargain for long-term investors.

3 Ways to Play the Bounce in Biotech Stocks

Biotech stocks delivered big this year for investors pursuing an aggressive growth strategy, driven by exciting new treatments for dread diseases like cancer, multiple sclerosis, hepatitis and HIV. And some have room to run in 2015.